| Revision as of 09:59, 20 November 2015 editDePiep (talk | contribs)Extended confirmed users294,285 editsm Identifier not assigned: use =none (CAS RN, ChemSpider, ATC) (via AWB script)← Previous edit |
Latest revision as of 23:49, 5 April 2023 edit undoEntranced98 (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers172,984 edits Adding local short description: "Monoclonal antibody", overriding Wikidata description "chemical compound"Tag: Shortdesc helper |
| (7 intermediate revisions by 7 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Monoclonal antibody}} |
|
{{Drugbox |
|
{{Drugbox |
|
| Verifiedfields = changed |
|
| Verifiedfields = changed |
|
|
| Watchedfields = changed |
|
| verifiedrevid = 470620672 |
|
| verifiedrevid = 470620672 |
|
| image = |
|
| image = |
| Line 28: |
Line 30: |
|
| CAS_number_Ref = {{cascite|changed|??}} |
|
| CAS_number_Ref = {{cascite|changed|??}} |
|
| CAS_number = 502496-16-4 |
|
| CAS_number = 502496-16-4 |
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
|
| UNII = 232D35B3NT |
|
| ATC_prefix = none |
|
| ATC_prefix = none |
|
| ATC_suffix = |
|
| ATC_suffix = |
| Line 33: |
Line 37: |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank = |
|
| DrugBank = |
|
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| ChemSpiderID = none |
|
| ChemSpiderID = none |
|
<!-- Chemical data --> |
|
<!-- Chemical data --> |
|
| C=6414 | H=9934 | N=1718 | O=2010 | S=40 |
|
| C=6414 | H=9934 | N=1718 | O=2010 | S=40 |
|
| molecular_weight = 144.6 ] |
|
|
}} |
|
}} |
|
|
|
|
|
'''Urtoxazumab''' is a ] against ] caused by '']'', serotype ]. The drug is designed to bind to a ] of this bacterium, so that it can be more easily broken down and eliminated from the body.<ref>, ''World Health Organization''.</ref><ref>{{cite journal|year=2009|last1=López|first1=EL|last2=Contrini|first2=MM|last3=Glatstein|first3=E|last4=González Ayala|first4=S|last5=Santoro|first5=R|last6=Allende|first6=D|last7=Ezcurra|first7=G|last8=Teplitz|first8=E|last9=Koyama|first9=T|last10=Matsumoto|first10=Y.|last11=Sato|first11=H.|last12=Sakai|first12=K.|last13=Hoshide|first13=S.|last14=Komoriya|first14=K.|last15=Morita|first15=T.|last16=Harning|first16=R.|last17=Brookman|first17=S.|title=Safety and Pharmacokinetics of Urtoxazumab, a Humanized Monoclonal Antibody Against Shiga-Like Toxin 2 in Healthy Adults and Pediatric STEC- Infected Patients|doi=10.1128/AAC.00343-09|journal=Antimicrobial agents and chemotherapy|pmid=19822704|volume=54|pages=239–243|issue=1|pmc=2798559|display-authors=8}}</ref> |
|
'''Urtoxazumab''' is a ] against ] caused by '']'', serotype ]. The drug is designed to bind to a ] of this bacterium, so that it can be more easily broken down and eliminated from the body.<ref>{{cite web | url = http://whqlibdoc.who.int/druginfo/18_1_2004_INN.pdf | title = International Nonproprietary Names for Pharmaceutical Substances (INN) | publisher = World Health Organization }}</ref><ref>{{cite journal | vauthors = López EL, Contrini MM, Glatstein E, González Ayala S, Santoro R, Allende D, Ezcurra G, Teplitz E, Koyama T, Matsumoto Y, Sato H, Sakai K, Hoshide S, Komoriya K, Morita T, Harning R, Brookman S | display-authors = 6 | title = Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli | journal = Antimicrobial Agents and Chemotherapy | volume = 54 | issue = 1 | pages = 239–43 | date = January 2010 | pmid = 19822704 | pmc = 2798559 | doi = 10.1128/AAC.00343-09 }}</ref> |
|
|
|
|
|
== References == |
|
== References == |
|
|
{{reflist}} |
|
<references/> |
|
|
|
|
|
|
{{Monoclonals for infectious disease and toxins}} |
|
{{Monoclonals for infectious disease and toxins}} |
|
|
|
|
|
] |
|
] |
|
|
] |
|
|
|
|
|
|
|
|
{{antiinfective-drug-stub}} |
|
{{antiinfective-drug-stub}} |
